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Abstract
Objective: To assess whether high levels of cerebrospinal fluid neurogranin are
found in atypical as well as typical Alzheimer’s disease. Methods: Immunoas-
says were used to measure cerebrospinal fluid neurogranin in 114 participants
including healthy controls (n = 27), biomarker-proven amnestic Alzheimer’s
disease (n = 68), and the atypical visual variant of Alzheimer’s (n = 19) accord-
ing to international criteria. CSF total-tau, Ab42, and neurofilament light con-
centrations were investigated using commercially available assays. All affected
individuals had T1-weighted volumetric MR images available for analysis of
whole and regional brain volumes. Associations between neurogranin, brain
volumes, total-tau, Ab42, and neurofilament light were assessed. Results:
Median cerebrospinal fluid neurogranin concentrations were higher in typical
and atypical Alzheimer’s compared to controls (P < 0.001 and P = 0.005). Both
neurogranin and total-tau concentrations, but not neurofilament light and
Ab42, were higher in typical Alzheimer’s compared to atypical patients
(P = 0.004 and P = 0.03). There were significant differences in the left
hippocampus and right and left superior parietal lobules in atypical patients,
which were larger (P = 0.03) and smaller (P = 0.001 and P < 0.001), respec-
tively, compared to typical patients. We found no evidence of associations
between neurogranin and brain volumes but a strong association with total-tau
(P < 0.001) and a weaker association with neurofilament light (P = 0.005).
Interpretation: These results show significant differences in neurogranin and
total-tau between typical and atypical patients, which may relate to factors
other than disease topography. The differential relationships between
neurogranin, total-tau and neurofilament light in the Alzheimer’s variants,
provide evidence for mechanistically distinct and coupled markers of neurode-
generation.
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Introduction
Synapses are the fundamental units that mediate neuronal
communication. Their plasticity underlies learning and
memory, through mechanisms including long-term
potentiation (LTP) and depression (LTD). There is sub-
stantial evidence that synapse loss is an early event in Alz-
heimer’s disease (AD), preceding neuronal cell death and
cognitive decline and is found throughout the neuropil
without any clear relation to amyloid plaques.1–3
Biomarkers of synapse dysfunction or loss could poten-
tially be useful in identifying Alzheimer’s disease patients
in the predementia stage as well providing information
about disease pathophysiology that could have utility in
clinical drug trials. Neurogranin (Ng) has recently
emerged as a potential synaptic biomarker. It is a postsy-
naptic protein that is mainly expressed in the cortex and
hippocampus, where it is concentrated in dendritic spines,
and has a major role in regulating LTP and learning.
Cerebrospinal (CSF) Ng is elevated in patients fulfilling
clinical criteria for AD compared to mild cognitive
impairment (MCI) patients as well as controls, a finding
that has been replicated using different assays and across
clinical sites.4–7 Importantly, it has not yet been deter-
mined if it is also elevated in atypical forms of AD.
In contrast with many other CSF biomarkers, Ng eleva-
tion appears to be specific for AD and is not significantly
raised in a number of other non-AD dementias and
parkinsonian conditions.8,9 Given that synaptic dysfunc-
tion and neurodegeneration are common to a number of
neurodegeneration diseases, the reason for this specificity
is unclear. It might relate to the anatomical focus of the
disease, noting that Ng is highly expressed in the amyg-
dala, hippocampi and cortical regions,10,11 areas typically
and prominently involved in AD, although there is also
prominent hippocampal involvement in some forms of
frontotemporal dementia (FTD).12 An alternative explana-
tion is that it is specific to the pathological process that
underpins AD. For example there is evidence that selec-
tive impairment of the translocation of Ng mRNA from
the cell body to the dendrites, which is seen in AD, is not
found in neurons from FTD patients.13
One way of exploring these possibilities in vivo is by
exploiting the phenotypic variation that is seen in AD.
While most patients present with amnestic symptoms,
others can present with nonamnestic phenotype,14 includ-
ing posterior cortical atrophy (PCA), sometimes referred
to as the visual variant of AD, where focus of neurode-
generation is, at least initially, restricted to the parietal/
occipital lobes with relative sparing of hippocampal and
temporal lobe volumes. In this study, we hypothesized
that patients with PCA due to AD would have lower con-
centrations of Ng than patients with typical AD, and that
this would relate to the degree of medial temporal lobe
involvement.
Materials and Methods
We studied 114 participants seen at clinics at the National
Hospital for Neurology and Neurosurgery, all of whom
had a clinical assessment and CSF examination. In addi-
tion the AD patients had magnetic resonance imaging
(MRI) brain scanning available for analysis. The study
was approved by the local ethics committee and all
participant gave written consent.
Study participants
Participants included 68 patients with amnestic AD accord-
ing to International Working Group 2 (IWG-2) criteria14
with an AD-indicative CSF AD biomarker profile (T-tau/
Ab42 >0.52)
15; 19 patients with PCA, also with a CSF T-tau/
Ab42 >0.52, according to Tang-Wai criteria and fulfilling the
latest international criteria for diagnosis of “PCA-AD”16,17;
and 27 controls who were spouses or friends of patients with
no history or symptoms of neurodegenerative disease at the
time of lumbar puncture (LP). These healthy individuals
underwent a thorough neurological examination, as well as
a standardized neuropsychological assessment using the
Mattis Dementia Rating Scale.18,19 To ensure a “pure” group
of healthy controls, we excluded those who had either Ab42
<550 pg/mL or a T-tau/Ab42 >0.52 or both.
15
Disease duration was recorded as the time in months
from reported symptom onset to LP. Patients underwent
Mini Mental State Examination (MMSE) for grading of
global cognitive ability20 as well as examinations of CSF
biomarker profiles. MMSE data were not available for 11
subjects.
CSF analysis
A standardized protocol for the collection and storage of
CSF was followed.21 Briefly, CSF was collected in sterile
polypropylene tubes, centrifuged at 4000 rpm for 10 min
at +40°C. The supernatant was divided into 0.5 mL
aliquots that were stored at 80°C.
CSF total tau (T-tau) and Amyloid b 1–42 (Ab42) con-
centrations were measured using INNOTEST enzyme-
linked immunosorbent assays (ELISAs) (Fujirebio Europe
N.V., Gent, Belgium). CSF neurofilament light (NFL)
concentration was measured using the NF-Light kit
(UmanDiagnostics, Umea, Sweden). All analyses were per-
formed by board-certified laboratory technicians blinded
to clinical information.
CSF Ng concentration was measured using one
immunoassay with two different detection methods, to
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incorporate samples previously analysed and increase the
sample size:
(1) Enzyme-linked immunosorbent assay (ELISA). 71
CSF samples from amnestic AD (n = 49), PCA (n = 14)
and control participants (n = 8), were measured using an
ELISA assay for Ng; (2) MSD platform. 43 samples were
run on an MSD platform (Meso Scale Discovery, Rock-
ville, MD, USA), including amnestic AD (n = 19), PCA
(n = 5) and controls (n = 19), to measure CSF Ng, as
previously described.9
The monoclonal antibody Ng7, which recognizes the
C-terminus of Ng (epitope Ng52–65) and has been found
to be optimal for ELISA, was used as a capturing anti-
body.4 Ng7 was coated on 96-well microtiter plates at a
final concentration of 1.0 lg/mL (100 lL/well) in carbon-
ate buffer (50 mmol/L NaHCO3). For MSD Ng7 was
coated on 96-well microtiter plates in a final concentra-
tion of 2.0 lg/mL, 40 lL/well in PBS. Both assays were
incubated overnight, ELISA-plate at +4°C and MSD in
room temperature.
After incubation the plates were washed four times
with PBS containing 0.05% Tween (PBS-Tween): for
ELISA-plates using a washing machine (Tecan hydro-
speed) for MSD washed by hand Blocking was performed
using a 1% BSA, PBS and 0.05% tween solution for
ELISA-plates and for MSD-plates using MSD blocker A-
solution (1.25 g) MQ H2O 20 mL and PBS (1.259). A
secondary polyclonal antibody (Upstate) diluted 1:10,000
for ELISA-plates in 1% BSA, PBS and 0.05% tween, for
MSD diluted 1:20,000 in 0.1% BSA-PBS-tween, and sam-
ples, calibrators, blanks and controls were added to the
plate in equal amount, (50 lL of each solution/well). The
plates were incubated for 1 h at room temperature,
700 rpm, and thereafter over night at +4°C (ELISA-
plates) or in room temperature (MSD-plates).
The next day, for ELISA, an anti-rabbit (from donkey)
conjugated to horse-radish peroxidase (HRP) (Sigma)
secondary antibody was added (diluted 1:20,000 in 1%
BSA, PBS and 0.05% tween) and incubated in the plate
for 5 h at room temperature. For MSD assay a goat anti-
rabbit sulfotag (0.5 lg/mL) was added and incubated for
2 h in room temperature.
The ELISA reading was performed using Tetramethyl
benzidine (TMB) substrate (TMB peroxidase EIA sub-
strate kit). TMB was added and incubated in the plate for
30 min at room temperature and protected from light.
The color reaction was stopped by adding 2 mol/L sulfu-
ric acid. The plate was read on a spectrophotometer
(Vmax) at 450 and 650 nm as reference wavelength and
the concentration of Ng was calculated using a 4-para-
metric equation. As calibrator, a full-length recombinant
Ng with concentrations ranging between 8000–62.5 pg/mL
was used in eight different concentrations. The lower and
higher limits of quantification were 125 and 4000 pg/mL,
respectively. Intra-assay coefficients of variation (CV) were
8% for a high concentration Ng control.
For the MSD assay, the reading was performed with
MSD read buffer (29) using electrochemiluminescence
(Meso Scale Discovery). The same calibrator was used as
for ELISA measurement but ranging between 31.3–
4000 pg/mL, 8-different concentrations.
Altogether 16 values were truncated, because they were
below the lower limit of quantification.
MRI acquisition and processing
T1-weighted volumetric MR images were acquired on
three different scanners (one 3.T Siemens Trio unit and
two 1.5T Signa units) using spoiled gradient recalled or
gradient echo (MPRAGE) sequences for amnestic- and
PCA-AD patients (scans were not acquired for control
participants). The scans consisted of full brain coverage
coronal or sagittal slices running between 124 and 208
contiguous slices of 1.5 or 1.1 mm. Whole-bran volume
was obtained using geodesic information flows (GIF).22
Briefly, for the volumetric analysis, brain was parcellated
into 143 nonoverlapping regions using a multi-atlas seg-
mentation propagation approach following the brainCO-
LOR protocol [http://www.braincolor.org/protocols/docs/
BrainCOLOR_cortical_parcellation_protocol.pdf] for deep
grey matter regions and the Neuromorphometrics proto-
col [http://www.neuromorphometrics.org:8080/seg] for
cortical regions.22 Regions of interest (ROIs) included
right and left hippocampus, entorhinal cortex, angular
gyrus, parahippocampal gyrus, superior parietal lobule
and the frontal and occipital cortex. Total intracranial
volume (TIV) was calculated using the Statistical Para-
metric Mapping (SPM) 12 software, version 6470 (www.f
il.ion.ucl.ac.uk/spm), running under Matlab R2014b
(Math Works, Natick, MA, USA).23
Statistical analysis
All analyses were carried out using Stata version 14. Glo-
bal tests for differences between amnestic AD, PCA and
controls for gender, age at lumbar puncture, disease dura-
tion at lumbar puncture, MMSE, and CSF biomarkers
were carried out and pairwise comparisons investigated if
the global test was statistically significant; differences in
brain region volumes between amnestic AD and PCA
were explored. These tests used linear regression (allowing
for variability to differ between groups where necessary),
Fisher’s exact, Mann–Whitney U test, and Kruskal–Wallis
followed by Dunn’s Test, as appropriate.
All analyses involving Ng allowed for there being two
Ng assay platforms and the truncated lower Ng values.
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Data were available for 18 individuals with both ELISA
and MSD Ng assay values; 11 were from this study’s
ELISA group and seven were not eligible for this study.
Using these data, a censored normal linear regression,
which allowed for truncated lower values, of ELISA Ng
on MSD Ng provided estimated regression coefficients
that were used to convert this study’s 43 MSD assay Ng
measures to the ELISA scale: ELISA = 60.54924 +
(0.7723643 9 MSD). The combined dataset (N = 114)
comprised 71 ELISA Ng measures and the 43 MSD to
ELISA converted Ng measures.
All CSF Ng values were log transformed to improve
normality. Estimates of the pairwise differences in Ng
between controls and the two patient groups were
obtained using a censored normal regression model, to
allow for truncated values, adjusting for age at LP, gender
and whether or not the Ng value had been converted (“-
say type”). The model allowed for variability to differ
between patient groups and also between the unconverted
and converted Ng groups.
Subsequent analyses used the same type of model and
adjustment variables but did not include controls, for
whom brain imaging data were not available; these analy-
ses also additionally adjusted for time between diagnosis
and lumbar puncture (“disease duration”). Combining
the PCA and amnestic AD patient groups, we estimated
the association between log-transformed Ng and four CSF
biomarkers (Ab42, T-tau, log-transformed Tau/Ab42 ratio
and NFL). Finally, we estimated the association between
log-transformed Ng and brain volume measures (whole
brain, average hippocampi, right and left hippocampi,
right and left entorhinal, right and left parahippocampal
gyrus, right and left angular gyrus, right and left superior
parietal lobules, right and left frontal cortex and right and
left occipital cortex), additionally adjusting for TIV. All
results on the log-transformed scale were back-trans-
formed to geometric means, and percentage differences
between such geometric means, as appropriate.
As a sensitivity analysis, all analyses were repeated using
the smaller dataset (N = 71) of only the participants who
had ELISA data. This removed the issue of converted data
and reduced the proportion of truncated data.
Results
Demographic and core CSF biomarker
information
Demographic, core CSF AD biomarker characteristics, and
differences between the participant groups, are shown in
Table 1. We found differences in age across the groups with
controls being statistically significantly younger than the
amnestic AD and PCA groups (P < 0.01 for both
comparisons with controls). The mean disease duration was
longer in the PCA group than the amnestic AD group
(P = 0.04). Observed median MMSE scores were the same
for the two patient groups and the distributions similar (25th
%tile – 75th %tile: PCA 20–26; amnestic AD 16–26) and, as
expected, higher in controls (29–30). Both amnestic AD and
PCA patients had significantly lower mean CSF Ab42 levels
(374 and 367 pg/mL, respectively) than controls (1058 pg/
mL) and higher median T-tau values (762 and 511 pg/mL,
respectively) than controls (256 pg/mL) (P ≤ 0.0001 for all
comparisons with controls); median T-Tau was also 50%
higher in amnestic AD than PCA (P = 0.03). As expected,
the amnestic AD and PCA groups had a higher median T-
tau/Ab42 ratio (2.15 and 1.45, respectively) than controls
(0.26) (P < 0.0001 for both comparisons with controls).
Median CSF NFL levels were higher in the amnestic AD and
PCA groups (1408 and 1360 pg/mL, respectively) than con-
trols (560 pg/mL) (P < 0.0001 for both comparisons with
controls). There were no statistically significant differences
between amnestic AD and PCA CSF for Ab42 (P = 0.83),
Tau/Ab42 (P = 0.11), NFL (P = 0.49).
CSF Ng in AD and PCA patients
CSF Ng concentrations for the combined dataset were
higher in amnestic AD patients (median 466.0 pg/mL,
25th %tile–75th %tile 294.0–684.5) compared to PCA
patients (median 370.2 pg/mL, 239.7–417.5) and controls
(218.9 pg/mL, 153.2–291.2) (Fig. 1). See Table 1 for sepa-
rate ELISA and unconverted MSD assay medians and
ranges. After adjustment for age at LP, gender, assay type,
and allowing for truncated values (see Statistical analysis
section), geometric mean CSF Ng concentrations were an
estimated 137.1% higher in amnestic AD patients (95%
CI 68.9–233.0), and 67.8% higher in PCA patients (95%
CI 16.7–141.2), than controls (P < 0.001 and P = 0.005
respectively). CSF Ng levels were an estimated 41.3%
higher in amnestic AD patients than PCA patients (95%
CI 12.0–78.4) (P = 0.004). When comparing the two
patient groups only, and after additionally adjusting for
disease duration, CSF Ng concentrations were an esti-
mated 30.7% higher in amnestic AD patients (95% CI
3.5–65.0) compared to PCA patients (P = 0.025).
Regional brain volumes in AD variants
Whole and regional brain volumes were compared between
amnestic AD and PCA patients (Table 2). After adjusting for
TIV, whole brain volume was on average 27,333 mm3 smaller
(95% CI 56,625 smaller —1959 larger) in PCA patients,
although this was not found to be statistically significant
(P = 0.07). Evidence of statistically significant differences in
regional brain volumes between the patient groups, after
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adjusting for TIV, were found in the left hippocampus, which
was on average 223 mm3 larger (95% CI 19–426; P = 0.03)
in the PCA group (observed mean 3457 mm3) compared to
amnestic AD patients (3209 mm3); the right superior parietal
lobule, which was on average 975 mm3 smaller (95% CI
1556–394; P = 0.001) in the PCA group (observed mean
6601 mm3) compared to amnestic AD patients (7501 mm3);
and in the left superior parietal lobule, which was on average
1081 mm3 smaller (95% CI 1567–596; P < 0.001) in the
PCA group (observed mean 6634 mm3) compared to amnes-
tic AD patients (7637 mm3). There were no significant differ-
ences in frontal lobe volumes between groups, but, as
expected, occipital lobe volumes were smaller in PCA
compared to AD (P = 0.01 right, P = 0.03 left, Table 2). No
statistically significant differences were found for other brain
regions and there was no material difference in P values
reported in Table 2 after adjusting for age at LP, gender and
disease duration.
Associations between CSF Ng and regional
brain volumes and CSF AD biomarkers
We investigated associations between CSF Ng and whole
and regional brain volumes as well as the core CSF
biomarkers including T-tau, Ab42, tau/ Ab42ratio and
NFL in the patient group dataset. These models adjusted
Table 1. Demographic and CSF biomarker characteristics of 114 participants.
PCA Amnestic AD Controls P*
N 19 68 27
Gender, female/male (% female) 12/7 (63.2%) 43/25 (63.2%) 16/11 (59.3%) G: 0.96a
Age at LP (years) 65.6 (6.9)
[55–80]
63.1 (6.6)
[48–80]
58.6 (8.5)
[43–71]
G: 0.003b
PvC: 0.001b
AvC: 0.006b
PvA: 0.19b
Disease duration at
LP (months)
55.5 (25.3)
[15–96]
42.1 (22.4)
[9–120]
N/A PvA: 0.04c
MMSE 23 (20–26)
[11–29]
(Missing = 2)
23 (16–26)
[2–30]
(Missing = 9)
30 (29–30)
[28–30]
G: 0.0001d
PvC: <0.0001d
AvC: <0.0001d
PvA: 0.44d
Ab42 (pg/mL) 367.1 (120.6)
[117–629]
374.1 (156.3)
[101–729]
1058 (239.7)
[568–1601]
G: <0.0001e
PvC: <0.001e
AvC: <0.001e
PvA: 0.83e
T-tau (pg/mL) 511 (412–690)
[299–977]
762 (453–1045)
[135–2722]
256 (188–338)
[107–473]
G: 0.0001d
PvC: 0.0001d
AvC: <0.0001d
PvA: 0.03d
Tau/Ab42 ratio 1.45 (1.03–2.11)
[0.64–6.93]
2.15 (1.09–3.78)
[0.54–11.88]
0.26 (0.20–0.30)
[0.13–0.33]
G: 0.0001d
PvC: <0.0001d
AvC: <0.0001d
PvA: 0.11d
NFL (pg/mL) 1360 (1149–1539)
[911–2157]
1408 (1112–1853)
[424–4446]
(Missing=1)
560 (444–808)
[257–2232]
G: 0.0001d
PvC: <0.0001d
AvC: <0.0001d
PvA: 0.49
Ng (pg/mL) ELISA (n = 14)
372.6 (273.0, 468.0)
[193.3–629.3]
MSD (n = 5)
232.0 (120.0, 334.0)
[120.0–462.2]
ELISA (n = 49)
501.0 (328.7, 724.9)
[125.0–1516.0]
MSD (n = 19)
474.9 (264.3, 623.9)
[120.0–2483.9]
ELISA (n = 8)
256.3 (125.0, 331.9)
[125.0–363.8]
MSD (n = 19)
195.8 (120.0, 296.7)
[120.0–838.6]
See text (Results)
LP, lumbar puncture; MMSE, mini mental state examination; Ab42, amyloid-beta 1–42; T-tau, total tau; NFL, neurofilament light; Ng, neurogranin.
The values presented are median (25th, 75th %tile) [range], except for Gender, Age at LP (years), Disease duration (months), and Ab42 (pg/mL)
which are presented as mean (SD) [range] or number (percentage), as appropriate. *P-values are shown for: G: a global test: null hypothesis is no
differences between the groups; PvC, PCA versus Amnestic AD; AvC, Amnestic AD versus PCA; PvC, PCA versus Amnestic AD.
aFisher’s exact; bordinary least squares linear regression; cMann–Whitney U test; dKruskal–Wallis and Dunn’s test; egeneralized least squares linear
regression, allowing for variability to differ between groups.
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for age at LP, gender, assay type, disease duration and,
when modeling brain volume regions, TIV. We found no
statistically significant evidence of associations between
CSF Ng and whole brain and individual regional
volumes.
Ng was strongly associated with T-tau (P < 0.001) in
the patient group dataset, with an estimated adjusted
0.11% (95% CI 0.08–0.13) increase in the geometric mean
of CSF Ng for every 1 pg/mL increase in T-tau. There
was no evidence (P = 0.70) of an association with Ab42
(estimated adjusted 0.02% (95% CI 0.07 to 0.11)
increase in Ng for every 1 pg/mL increase in Ab42) but a
strong association was, as expected, found with Tau/ Ab42
ratio (P < 0.001), with an estimated 0.44% increase (95%
CI 0.26–0.61) in the geometric mean of Ng for every 1%
increase in the geometric mean of T-tau/ Ab42 ratio.
There was also evidence of an association with NFL
(P = 0.005), with an estimated adjusted 0.03% increase
(95% CI 0.01–0.05) in the geometric mean of Ng for
every 1 pg/mL increase in NFL.
Sensitivity analysis
Rerunning the analyses using only the 71 participants
with ELISA assay Ng data produced results that were con-
sistent with those reported above using the full dataset
(data not shown).
Discussion
The main findings of this study are: (1) that compared to
controls, CSF Ng is elevated in both amnestic AD and
PCA-AD, and that Ng is significantly higher in amnestic
AD compared to PCA-AD; (2) CSF Ng levels are strongly
associated with T-tau and less strongly with NFL; (3) T-
tau levels but not NFL or Ab42 are significantly different
between AD and PCA-AD; and (4) despite there being
significant differences in the expected regional brain vol-
umes between amnestic AD and PCA-AD, there were no
significant relationships between Ng levels and brain
volumes.
Although a number of studies have demonstrated ele-
vated levels of Ng in AD, this is to our knowledge the
first study to explore CSF Ng in different AD phenotypes.
We confirm previous findings that Ng is elevated in “typ-
ical” AD, extending it to demonstrate that it is also ele-
vated in one of the canonical AD variants, PCA. While
PCA is not invariably due to AD, Alzheimer pathology is
the commonest underlying cause, and our cases all had a
core CSF biomarker signature in keeping with AD, pro-
viding further evidence for Ng being a specific marker for
AD. However, our finding that Ng levels in PCA were
intermediate between controls and typical AD and signifi-
cantly different from both – independent of disease sever-
ity – suggests that variation in Ng level is likely due to
other factors, for example difference in disease topology
or to other pathological mechanisms.
Previous studies have shown that individuals presenting
with the visual variant of AD, PCA, have proportionately
more regional atrophy, cortical thinning and tau deposi-
tion in the occipitoparietal regions than hippocampi and
other medial temporal structures compared to those with
typical memory led AD.24–26 Our imaging findings are
broadly in keeping with these, with the PCA patients hav-
ing larger hippocampal and small parietal lobe volumes
than patients with typical AD. Previous studies have
shown correlations between CSF Ng and whole brain vol-
ume and regional volumes, including the mesial temporal
lobe, entorhinal cortex, hippocampus and parrahip-
pocampus.27,28 Conversely, this trend has not been
observed in other brain regions, supporting the hypothe-
sis that Ng release may be more likely to occur when neu-
rodegeneration involves these areas. We were unable to
demonstrate relationships between Ng concentration and
regional volume across the patient cohort. There are a
number of possible reasons for this. The elevated Ng in
AD may not be specific to hippocampal atrophy and may
represent more widespread global degeneration, perhaps
in AD related areas including the parietal cortex. Our
results may be a consequence of small sample size and
the cross-sectional nature of this study, noting that previ-
ous studies have reported no association between CSF Ng
and hippocampal volumes in a similar cross-sectional
analysis6; it may be that rates of atrophy derived from
longitudinal assessments would better reflect the rate of
synaptic loss. Finally, the CSF levels of neuronal and
Figure 1. Scatter plots displaying CSF Ng concentrations (Elisa-
including converted MSD to Elisa values) in controls and AD variants.
The lower, middle, and upper lines of the box correspond to the 25th
%tile, median, and 75th %tilerespectively. Ng, neurogranin; PCA,
posterior cortical atrophy.
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synaptic proteins such as tau and Ng are believed to
reflect the state (or intensity) of the degenerative process,
while MRI measurements of cortical volumes reflect the
stage of degeneration,29 and thus these measures may not
be expected to correlate well.
To explore differential pathological mechanisms, we
compared other AD-related biomarkers between PCA and
amnestic AD. There were no significant differences in
Ab42 or NFL, but similar to the Ng findings, T-tau was
significantly lower in PCA than typical AD. When we
compared levels with other AD biomarkers, we similarly
observed no association between Ng and CSF Ab42 levels.
This is perhaps not surprising, since amyloid deposition
probably occurs many years before synaptic loss and neu-
rodegeneration,30 and previous studies have shown no
correlation between synaptic loss and amyloid plaque
burden. In keeping with other studies,7 we did however
find T-tau and Ng levels to be strongly associated (which
would also be in keeping with reports of lower levels of
CSF T-tau in PCA compared to other AD pheno-
types31,32), and a relationship – albeit not as strongly –
between Ng and NFL.
While all are ostensibly markers of neurodegeneration,
these three proteins are not thought to be mechanistically
linked but thought to have very different roles in neu-
ronal cell physiology. The exact biological role of T-tau is
not clear; it is from a biomarker perspective thought to
be a surrogate marker of neurodegeneration33 which is
elevated in AD and some other neurodegenerative dis-
eases, although interestingly not in all tau-opathies. How-
ever, it is becoming apparent that tau may not be a
simple damage biomarker, but is secreted from cells
under physiological conditions, a process which is regu-
lated by neuronal activity.34,35NFL is a marker of large
fiber myelinated axonal degeneration,36 is elevated in neu-
rodegeneration independent of amyloid deposition,27 and
has been shown to be a prognostic marker in a large
number of different neurodegenerative conditions.37,38 By
Table 2. Regional brain volumes compared between AD and PCA.
PCA Amnestic AD P*
N 19 68
Whole brain (mm3) 951,948 (86,033)
[797,538–1142903]
969,757 (126,099)
[655,039–1314248]
0.07a
Right hippocampus (mm3) 3514 (604)
[ 2256–4584]
3336 (449)
[ 2291–4303]
0.18b
Left hippocampus (mm3) 3457 (484)
[2574–4249]
3209 (435)
2174–4141]
0.03b
Right EC (mm3) 2253 (355)
[1462–2811]
2212 (349)
[1435–3150]
0.83b
Left EC (mm3) 1954 (293)
[1438–2452]
1896 (286)
[1211–2524]
0.52b
Right PHG (mm3) 2892 (532)
[2062–3828]
2894 (400)
[2073–3831]
0.63b
Left PHG (mm3) 3166 (565)
[2186–4099]
3064 (432)
[2238–4050]
0.47b
Right AG (mm3) 6454 (1213)
[4313–8436]
6598 (1231)
[3839–9522]
0.43b
Left AG (mm3) 6118 (1084)
[4432–8624]
6341 (1279)
[3848–9971]
0.31b
Right SPL (mm3) 6601 (1546)
[3692–9704]
7501 (1200)
[4987–9811]
0.001b
Left SPL (mm3) 6634 (1303)
[4541–8899]
7627 (1417)
[4203–10,541]
<0.001a
Right frontal (mm3) 117,454 (10,627)
[98,247–134,058]
113,799 (16,065)
[74,928–153,361]
0.36b
Left frontal (mm3) 117,674 (11,092)
[99,542–139,374]
113,732 (15,730)
[73,511–146,192]
0.30b
Right occipital (mm3) 40,392 (5798)
[31,240–52,095]
42,783 (6570)
[25,259–57,635]
0.01b
Left occipital (mm3) 38,567 (6443)
[25,675–53786]
40,677 (6025)
[28,131–56,436]
0.03b
EC, entorhinal cortex; PHG, parahippocampal gyrus; AG, angular gyrus; SPL, superior parietal lobule.
Data presented as (mean (SD), range [ ]); *P-values are shown for a pairwise test: null hypothesis is no differences between the groups, adjusting
for TIV; ageneralized least squares linear regression, allowing for variability to differ between groups; bordinary least squares linear regression.
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contrast, Ng is a synaptic marker, which does not appear
to be elevated in other degenerative diseases that involve
atrophy/degeneration in cortical regions,8,9 such as FTD,
suggestive of a mechanism of release independent of cell
death per se. In the case of AD, it is also not clear
whether Ng is released at the synapse during neuronal cell
death,39 or whether abnormal secretion occurs due to
other physiological stressors.
Our data therefore provide some new insights into the
relationship between T-tau, Ng and NFL. Ng is the only
marker that appears relatively specific for AD, and in
established AD, T-tau and Ng appear to be closely related.
This does however not necessarily imply that the two are
mechanistically linked, for which further work is required.
NFL by contrast, appears to be a measure of disease
intensity (i.e., prognosis) across a wide range of diseases,
likely through a mechanistically distinct and similar (i.e.,
long myelinated axons) process.
This study has a number of limitations. Two assay ver-
sions were used to quantify CSF Ng concentration but we
were able to allow for this by running some samples on
both platforms, both demonstrating a very tight correlation
between the values obtained in both (data not shown,
P < 0.0001) and allowing for appropriate conversion of
MSD assay values to the ELISA scale. We also demonstrate
consistency of results when the analyses were repeated
using only ELISA assay data. Our study contained relatively
small numbers of subjects, an inevitable consequence of
PCA being a relatively rare condition, but we note that our
numbers compare well to other similar studies.31,40 We did
not have longitudinal measures of biomarkers or atrophy
which would allow for a more detailed analysis of the
dynamic changes and relationships.
These results, of the present study, extend the finding
that Ng is a marker for AD pathology to atypical forms of
the disease, suggesting that it may be a useful diagnostic
marker across the AD spectrum. The lack of evidence for a
relationship between Ng and patterns of atrophy suggest
that the significant differences in Ng between patients with
amnestic AD and PCA-AD may relate to factors other than
disease topography, although this requires histopathologi-
cal confirmation. The differential relationships between Ng,
T-tau and NFL in PCA, amnestic AD, and across the spec-
trum of disease provide evidence for mechanistically dis-
tinct and variably coupled markers of neurodegeneration.
Measurement of all three may provide a means of assessing
the mechanistic effects of drug therapies targeting different
aspects of AD pathogenesis.
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